Henry Koon
Physician · Case Western Reserve University/University Hospitals Cleveland Medical Center
Credentials: · ·
History
Hematology and Medical Oncology
Internal Medicine
Research
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine · 2021 · 864 citations
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2018 · 495 citations
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Journal of Clinical Investigation · 2003 · 463 citations
9 papers
8 papers
7 papers
- BD
6 papers
4 papers
- AT
3 papers
- DL
3 papers
3 papers
Grants
- 2004–2008
Phase II Trial on Imatinib in Kaposi's Sacroma
National Cancer Institute · R21
Contact PI · $511.9K · Case Western Reserve University
- 2002–2008
NPM-ALK & CD30 Signaling in Anaplastic Cell Lymphoma
National Cancer Institute · K08
Contact PI · $651.6K · Beth Israel Deaconess Medical Center
- 2006–2008
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $39.3K · Beth Israel Deaconess Medical Center
Clinical trials
- 2009–2016
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Principal investigator · Terminated
Case Comprehensive Cancer Center
- 2005–2009
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
Study chair · Completed · Phase 2
AIDS Malignancy Consortium
- 1999–2007
Study chair · Completed · Phase 1
Beth Israel Deaconess Medical Center